Beaumont Hospital

At Beaumont Hospital in Dublin, the Infectious Diseases research portfolio includes studies in Virus Diseases, Respiratory Tract Diseases, and broader immune-related conditions. The trials focus on improving care for infections such as SARS-CoV-2 (COVID-19), mpox virus disease, and severe pneumonia, while also testing new treatment approaches for hospitalized patients.

• Evaluating new therapies for moderate and severe COVID-19 and other serious viral infections
• Studying clinical outcomes in mpox to better understand treatment value
• Assessing whether novel anti-inflammatory or antiviral strategies can improve recovery in severe community-acquired pneumonia

These studies aim to strengthen treatment options for acute infections and help identify which approaches work best in real-world hospital care.

The site is actively involved in Neoplasms research across several cancer types, including breast cancer, lung cancer, melanoma, ovarian cancer, prostate cancer, and renal cancer. Many of the trials are designed to compare new combination therapies with current standards of care and to improve survival, recurrence prevention, and disease control.

• Testing new treatment combinations for advanced solid tumors and metastatic cancers
• Evaluating therapies for early breast cancer and HER2-low breast cancer to reduce recurrence risk
• Studying improved options for small cell lung cancer, non-small cell lung cancer, and gastroesophageal adenocarcinoma

These cancer studies are focused on finding more effective, durable treatments and identifying better ways to delay progression or relapse.

Research at Beaumont Hospital also covers immune system diseases, digestive system diseases, and nutritional and metabolic diseases. Current trials include conditions such as ulcerative colitis, alpha-1 antitrypsin deficiency-associated liver disease, Addison’s disease, and congenital adrenal hyperplasia, reflecting a strong interest in long-term disease management and symptom control.

• Assessing new therapies for ulcerative colitis and related inflammatory bowel disease care
• Testing approaches for liver fibrosis in alpha-1 antitrypsin deficiency
• Studying treatments that may improve hormone balance and quality of life in adrenal disorders

These trials aim to improve everyday disease control, reduce complications, and support better long-term outcomes for patients with chronic conditions.

The clinical trial activity also includes cardiovascular and neurological research, with studies in stroke and care for critically ill patients. In addition, some trials examine supportive treatments used in intensive care settings, including approaches to sedation and bleeding control.

• Evaluating treatment strategies after intracerebral haemorrhage and stroke
• Studying sedation approaches in older critically ill patients receiving intensive care
• Assessing whether hospital-based therapies can improve survival and recovery in severe illness

These studies are intended to refine hospital practice, improve safety, and support better outcomes for patients with urgent and complex medical needs.

Additional work at the site includes hematologic malignancies such as chronic lymphocytic leukemia, multiple myeloma, and non-Hodgkin’s lymphoma, alongside research in genetic phenomena and targeted treatment strategies. This part of the portfolio reflects a broader focus on personalized medicine and long-term disease control.

• Exploring new options for previously untreated chronic lymphocytic leukemia and other blood cancers
• Studying targeted treatments that may improve control of advanced cancers and reduce recurrence
• Investigating therapies guided by genetic and biomarker-based disease features

These trials aim to match patients with more precise therapies and improve the effectiveness of treatment across complex cancer and endocrine conditions.